Antiproliferative Agents

Antiproliferative Agents

Antiproliferative medicines also known as antimetabolites are immunosuppressive medications that act by inhibiting cell-cycle pathways, lowering T- and B-cell multiplication, and thereby lessening the cytotoxic response directed against the cardiac allograft. Immunosuppressants are medications that aid in the suppression of the immune system's reaction to foreign substances. These drugs suppress the immune response, protect the donor organ and its function, and avoid organ rejection. They are most typically used to prevent autoimmune diseases such as arthritis, myasthenia gravis, Crohn's disease, lupus, and rheumatoid arthritis, as well as organ transplant rejections like kidney, liver, and heart transplants.

The Antiproliferative Agents Market is expected to grow at a strong CAGR of ~ 8.5% during the forecast period owing to the rising demand for organ transplants globally. Additionally, government initiatives and an increase in the geriatric population are driving the market. Furthermore, , the rise in the prevalence of chronic diseases coupled with an increase in the prevalence of autoimmune diseases is driving the market for antiproliferative agents.For instance, as stated by the national stemcells foundation nearly 4% of the world is affected by 1 or 80 different autoimmune diseases the most common autoimmune disease includes multiple sclerosis, rheumatoid arthritis, lupus, Crohn’s disease, psoriasis and scleroderma.

• Based on drug type, the market is segmented into immunosuppressants, alkylating agents, nitrosourea and others. Amongst these, the immunosuppressants segment dominated the market in 2021. This is because of the growing prevalence of autoimmune diseases and organ transplantation globally. For instance according to the Global Observatory Donation and Transplant (GODT) report, in 2021 the no. of organs transplanted increased from 1,44,302 in 2021 to 1,29,680 in 2020. This accounted for 11.3% in 2021 from 2020.
• Based on dosage form, the market is segmented into tablets, capsules, injections and others. Among these, the injectable segment will capture the majority share of the antiproliferative agents market in 2021. The major share of the injectables can be attributed to the advantages such as it can be administered to unconscious patients, lipophilic drugs can be administered, provides instance action, best suited for acid-labile drugs. This is the first choice of dosage form preferred by doctors.
• On the basis of the route of administration, the market is segmented into intravenous, oral, and others. The oral route of administration would hold a major share of the antiproliferative agents market in 2021 and is expected to grow at a substantial CAGR during the forecasted period. The oral route is the preferred route of choice for maintenance therapy, offers patient compliance, provides prolonged action, large therapeutic index.
• On the basis of indication the market is segmented as autoimmune, cancer, organ transplant, non-inflammatory disease and others. Amongst these, the cancer segment would hold the dominating share during the forecasting period. This is because of the, increase consumption of processed food & sugary beverages, sadatory lifestyle, obesity and increased alcohol consumption. For instance, according to World Health Organization (W.H.O.) report, in 2020, 7,40,000 new cancer cases due to alcohol consumption were registered. Amongst this oesophagus cancer holds the major share (25.6%) worldwide.
• On the basis of end-user, the market is segmented into hospitals pharmacies, retail pharmacies, and others end-uses. The hospital pharmacy segment end-use held a major share of the antiproliferative agents market in 2021 and is expected to grow at a substantial CAGR during the forecasted period. Furthermore, the consumer prefers the hospital pharmacy, as it offers easy access, while retail pharmacies have limited stocks only.
• For a better understanding of the market adoption of the Antiproliferative agent industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, UK, France, Italy, Spain and Rest of Europe), Asia-Pacific (China, Japan, India, and Rest of Asia-Pacific), Rest of World. North America dominated the antiproliferative agents market in 2021 due to the high healthcare expenditure. For instance, according to report Centers for Medicare & Medicaid Services, in 2021, the National Healthcare Expenditure (NHE) grew 2.7% to US$4.3 trillion in 2021, or $12,914 per person, and accounted for 18.3% of the Gross Domestic Product (GDP). Additionally, an increase in R&D infrastructure, favourable healthcare reimbursement policies and huge demand for organ transplants are the factors driving the market in this region.
• Some of the major players operating in the market include Accord Healthcare, F. Hoffmann-La Roche Ltd, Novartis Pharmaceuticals, Glenmark Pharmaceuticals U.S. Inc., GlaxoSmithKline, Johnson & Johnson Services, Inc., Cadila Pharmaceuticals., AstraZeneca LP, Lupin., Cipla Inc.